Belchatow

Researchers are evaluating ziltivekimab as a treatment for people living with heart failure and inflammation. This Phase 3 study compares ziltivekimab to a placebo in participants with heart failure who have mild to preserved ejection fraction and systemic inflammation. The study aims to assess the effect of ziltivekimab on cardiovascular death, heart failure hospitalization, or urgent heart failure visits over a period of up to 4 years. Participants will receive monthly injections of either ziltivekimab or a placebo using a pre-filled syringe or a pen-injector. The study medication is administered subcutaneously once a month for up to 4 years. The trial includes up to 20 clinic visits during which participants will be monitored and assessed. During the study, participants will use a study app on their phone to record all injections and complete questionnaires. Researchers will monitor participants for key outcomes like cardiovascular events and heart failure episodes from the time of randomization until the end of the study. Safety and health status will be regularly evaluated throughout the study period, which may last up to 48 months.

Researchers are evaluating the effects of SPT-300 (GlyphAllo), a prodrug of allopregnanolone, in adults aged 18 to 65 years who have major depressive disorder (MDD), with or without anxious distress. This Phase 2 study is randomized, double-blind, placebo-controlled, and aims to assess the efficacy, safety, and tolerability of SPT-300 as a monotherapy treatment for MDD. Participants will receive either SPT-300 or a placebo and will be monitored over a 42-day treatment period. The study compares the impact of SPT-300 to placebo on depressive symptoms and any side effects experienced. The intervention is given as a drug treatment, and participants are randomly assigned to one of the two groups. Throughout the study, researchers will measure changes in depression severity using the Hamilton Depression Rating Scale-17 (HAM-D-17) total score from the start of the treatment to day 42. Participants will be assessed for safety and tolerability, and their adherence to treatment will be monitored. The study focuses on the depressive episode lasting between 4 weeks and 18 months, with careful screening to ensure participant eligibility and safety.

Anterior Cruciate Ligament (ACL) Degeneratio Mucosa is a condition caused by mucoid degeneration of the ACL, which affects daily functioning. The exact cause of this condition is unknown. Previous treatments involved removing and reconstructing the ACL, but these methods may lead to worsened knee function. This trial is studying a new technique called ACL "decompression," which involves making longitudinal incisions and removing mucoid tissue outside the ligament fibers to improve symptoms. The treatment being evaluated is ACL "decompression," performed as a surgical procedure that creates longitudinal cuts in the ligament to evacuate extrafibrous mucoid tissue. This approach aims to relieve symptoms while preserving the ACL structure. Participants will undergo this procedure as their primary treatment during the study. Participants will be followed and assessed at 12 and 24 months after treatment. Researchers will measure knee range of motion and stability, including anterior translatory stability and anterolateral rotational stability. These assessments will help determine the effectiveness of the decompression technique in restoring knee function over time.

Researchers are evaluating the outcomes of a surgical procedure called Double-bundle Posterior Cruciate Ligament Reconstruction (DB-PCLR) for patients with Posterior Cruciate Ligament tears. This approach reconstructs both the anterolateral and posteromedial bundles of the ligament and is considered a more advanced technique compared to single-bundle reconstruction. It is studied to determine if it improves patients' knee stability and overall results after surgery. The study involves performing the DB-PCLR procedure on participants who have a grade III symptomatic posterior instability confirmed by clinical and radiological exams. The procedure aims to restore knee stability by reconstructing both bundles of the ligament. This approach is technically more complex but is thought to potentially offer better outcomes. Participants will be followed for 12 and 24 months after surgery to assess knee stability using various tests such as the posterior sag test, posterior drawer test, posterior Lachman test, stress X-ray, and internal rotation stability evaluation. These assessments will help measure the effectiveness of the reconstruction over time and monitor the knee's functional stability after the procedure.

Researchers are investigating whether the medicine vicadrostat, when taken together with empagliflozin, can lower the risk of heart-related problems in adults who have type 2 diabetes, high blood pressure, and cardiovascular disease but no history of heart failure. This study is a Phase III trial that compares the effects of vicadrostat plus empagliflozin to a placebo plus empagliflozin in people with these conditions. Participants are randomly assigned to one of two groups: one group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets that look like vicadrostat along with empagliflozin. All participants take one tablet daily for a period ranging from two and a half years up to four years and three months. Throughout the study, participants continue their usual medications for diabetes, high blood pressure, and cardiovascular disease. During up to 51 months of participation, participants visit the study site regularly where doctors collect health information and blood samples. Researchers track when participants experience cardiovascular events such as heart-related deaths or heart failure events. The study also monitors participants’ overall health and any side effects they may experience to assess the safety and effects of the treatments.

This research aims to evaluate the long-term safety and tolerability of NBI-1065845 when added to ongoing antidepressant treatment in adults diagnosed with Major Depressive Disorder (MDD). It focuses on participants who have experienced moderate or severe recurrent MDD or persistent depressive disorder and who have not responded adequately to oral antidepressants during their current depressive episode. This is a Phase 3, open-label study designed to monitor the effects of this adjunctive treatment over an extended period. Participants will receive NBI-1065845 tablets alongside their current oral antidepressant therapy. The study will observe treatment effects and monitor any adverse events that emerge during the course of therapy. There is no mention of a comparator or placebo group, indicating all enrolled individuals will be treated with NBI-1065845 in addition to their existing medication. The treatment and observation period extends through 52 weeks, allowing for comprehensive long-term safety assessment. During the study, participants will be regularly evaluated for treatment-emergent adverse events from the start through week 52. Researchers will track safety and tolerability through clinical assessments and monitoring. Participants must be willing and able to follow all study procedures and restrictions as determined by the investigators. The overall duration and detailed assessments ensure thorough monitoring of how well participants tolerate the adjunctive treatment over the course of one year.

Medial patellofemoral ligament (MPFL) injury happens in most cases of lateral patellar dislocations, often causing ongoing instability of the kneecap. This research aims to evaluate the outcomes of reconstructing the MPFL using a fascia lata allograft, guided by an isometry assessment, combined with the Elmslie-Trillat tibial tuberosity osteotomy procedure. The study focuses on patients who have experienced lateral patellar dislocation and instability and have not improved with non-surgical treatments. The treatment being studied involves MPFL reconstruction with a fascia lata allograft based on an isometry assessment, alongside the Elmslie-Trillat tibial tuberosity osteotomy. Any additional patellofemoral joint issues will be managed during the procedure. This combined surgical approach is designed to address the instability caused by the injury and improve patella stability. Participants will be assessed through various measures, including the International Knee Documentation Committee Questionnaire and the Knee injury and Osteoarthritis Outcome Score. Researchers will also monitor the rate of ligament retears. Patella stability will be tested using the apprehension and lateral luxation tests at 12 and 24 months after treatment to evaluate long-term outcomes and safety.

Researchers are evaluating the outcomes of a treatment for Posteromedial Tibiofemoral Incongruence (PMTFI), a condition affecting the knee joint. This condition involves a decrease in the curvature of the femoral metaphysis near the medial femoral condyle, which can compress the posterior horn of the medial meniscus (PHMM) during deep knee flexion. Symptoms such as pain and discomfort may arise, especially when conservative treatments have failed, leading to consideration of surgical intervention. The treatment being studied is an arthroscopic procedure designed to correct PMTFI with minimal necessary intervention. This technique allows surgeons to confirm during the operation whether repair of the posteromedial tibiofemoral incongruence is needed. The procedure aims to address the anatomical changes causing impingement and discomfort during full knee flexion. Participants will be monitored over a follow-up period of 24 months to assess the presence of pain during full knee flexion at 12 and 24 months. The study includes clinical assessments and imaging to confirm diagnosis and treatment effects. Safety and outcomes will be carefully tracked to evaluate the success of the procedure in relieving symptoms associated with PMTFI.